ACAD
Acadia Pharmaceuticals Inc (ACAD)
Healthcare • NASDAQ • $23.61+4.47%
- Symbol
- ACAD
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- Price
- $23.61
- Daily Change
- +4.47%
- Market Cap
- $3.70B
- Trailing P/E
- 9.78
- Forward P/E
- 24.21
- 52W High
- $28.35
- 52W Low
- $19.69
- Analyst Target
- $31.65
- Dividend Yield
- N/A
- Beta
- 0.83
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America. The company offers NUPLAZID (pimavanserin), a selective serotonin inverse agonist/antagonist for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 to treat the symptoms of Rett syndrome by reducing neuroinflammation and supporting synaptic function. It also develops remlifanserin, which is in phase 2 clinical trial for the treatment of alzheimer's disease psychosis and lewy body dementia psychosis; ACP-211, which is in phase 2 clinical trial to treat major depressive disorder; A…
Company websiteResearch ACAD on Stk-Ai
Stk-Ai gives you screening across 100+ fundamental metrics, AI-powered analysis, target predictions, backtested signals, and portfolio tracking — all in one place.
Data shown is for informational purposes only and is not investment advice. Prices and metrics may be delayed.